tildrakizumab

Modality

mAb

Mechanism

12.1 Mechanism of Action Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.

Targets

IL-23 (p19), IL-37

Storage

—

Approved

psoriasis — FDA

In trial

psoriasis, atopic dermatitis, vitiligo

Sources

DailyMed (FDA label)DrugBank ClinicalTrials.gov

Last verified

2026-04-23

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by tildrakizumab.

Monitoring & workup

Baseline workup

•TB IGRA (or PPD)
•HBV sAg if high risk; HCV Ab if high risk
•Update age-appropriate vaccines before start

Ongoing monitoring

•No routine labs
•Annual TB screening if high exposure risk
•IL-17 class: monitor for candida overgrowth + IBD flare
•IL-23 class: monitor for injection-site reactions